Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes

• DOI: 10.1128/aac.06477-11
• Publication Date: 2012-07-03T02:37:25Z
• Authors: Catherine A. Koss; Dana C. Baras; Sandra D. Lane; Richard Aubry; Michele Marcus; Lauri E. Markowitz; Emilia H. Koumans
• Keywords: Adult; Antifungal Agents; Adolescent; Fungi; Infant, Newborn; New York; Abnormalities, Drug-Induced; Infant, Low Birth Weight; 3. Good health; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Mycoses; Maternal Exposure; Pregnancy; Metronidazole; Prenatal Exposure Delayed Effects; Multivariate Analysis; Humans; Premature Birth; Female; Pregnancy Trimesters

ABSTRACT To assess whether treatment with metronidazole during pregnancy is associated with preterm birth, low birth weight, or major congenital anomalies, we conducted chart reviews and an analysis of electronic data from a cohort of women delivering at an urban New York State hospital. Of 2,829 singleton/mother pairs, 922 (32.6%) mothers were treated with metronidazole for clinical indications, 348 (12.3%) during the first trimester of pregnancy and 553 (19.5%) in the second or third trimester. There were 333 (11.8%) preterm births, 262 (9.3%) infants of low birth weight, and 52 infants (1.8%) with congenital anomalies. In multivariable analysis, no association was found between metronidazole treatment and preterm birth (odds ratio [OR], 1.02 [95% confidence interval [CI], 0.80 to 1.32]), low birth weight (OR, 1.05 [95% CI, 0.77 to 1.43]), or treatment in the first trimester and congenital anomalies (OR, 0.86 [0.30 to 2.45]). We found no association between metronidazole treatment during the first or later trimesters of pregnancy and preterm birth, low birth weight, or congenital anomalies.